Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) has announced its participation in Morgan Stanley's 22nd Annual Global Healthcare Conference. The company will be featured in a fireside chat on September 5, 2024, at 9:15 a.m. ET. This event presents an opportunity for investors and interested parties to gain insights into Royalty Pharma's operations and strategy.
The presentation will be accessible via webcast from the company's official website, specifically the 'Events' page in the Investors section. For those unable to attend live, the webcast will be archived for a minimum of thirty days, allowing for later viewing. This participation underscores Royalty Pharma's commitment to engaging with the investment community and sharing its perspective on the healthcare sector.
Royalty Pharma plc (Nasdaq: RPRX) ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Mondiale sulla Salute di Morgan Stanley. L'azienda sarà presente in un fireside chat il 5 settembre 2024, alle 9:15 ora ET. Questo evento offre un'opportunità per gli investitori e le parti interessate di ottenere informazioni sulle operazioni e sulla strategia di Royalty Pharma.
La presentazione sarà accessibile tramite webcast dal sito ufficiale dell'azienda, specificamente dalla pagina 'Eventi' nella sezione Investitori. Per coloro che non possono partecipare dal vivo, il webcast sarà archiviato per un minimo di trenta giorni, consentendo una visione successiva. Questa partecipazione sottolinea l'impegno di Royalty Pharma a interagire con la comunità degli investitori e a condividere la propria visione sul settore sanitario.
Royalty Pharma plc (Nasdaq: RPRX) ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. La empresa será presentada en un fireside chat el 5 de septiembre de 2024, a las 9:15 a.m. ET. Este evento representa una oportunidad para que inversores y partes interesadas obtengan información sobre las operaciones y la estrategia de Royalty Pharma.
La presentación estará disponible a través de webcast en el sitio web oficial de la empresa, específicamente en la página de 'Eventos' en la sección de Inversores. Para aquellos que no puedan asistir en vivo, el webcast será archivado por un mínimo de treinta días, permitiendo su visualización posterior. Esta participación subraya el compromiso de Royalty Pharma con la comunidad inversora y el deseo de compartir su perspectiva sobre el sector sanitario.
Royalty Pharma plc (Nasdaq: RPRX)는 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 이 회사는 2024년 9월 5일 오전 9시 15분 ET에 진행되는 화로 주변 대담에서 소개될 것입니다. 이 이벤트는 투자자와 이해 관계자들에게 Royalty Pharma의 운영 및 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
프레젠테이션은 회사 공식 웹사이트의 '이벤트' 페이지, 투자자 섹션에서 웹캐스트를 통해 접근할 수 있습니다. 실시간으로 참석할 수 없는 분들을 위해 웹캐스트는 최소 30일 동안 보관될 예정이며, 이후에 시청할 수 있습니다. 이번 참여는 Royalty Pharma가 투자 커뮤니티와 소통하고 헬스케어 분야에 대한 관점을 공유하겠다는 의지를 강조합니다.
Royalty Pharma plc (Nasdaq: RPRX) a annoncé sa participation à la 22e Conférence Annuelle Internationale sur la Santé de Morgan Stanley. L'entreprise sera mise en avant lors d'un entretien informel le 5 septembre 2024, à 9h15 ET. Cet événement représente une occasion pour les investisseurs et les parties intéressées d'obtenir un aperçu des opérations et de la stratégie de Royalty Pharma.
La présentation sera accessible via webcast à partir du site officiel de l'entreprise, plus précisément sur la page 'Événements' dans la section Investisseurs. Pour ceux qui ne peuvent pas assister en direct, le webcast sera archive pendant au moins trente jours, permettant une visualisation ultérieure. Cette participation souligne l'engagement de Royalty Pharma à dialoguer avec la communauté des investisseurs et à partager sa perspective sur le secteur de la santé.
Royalty Pharma plc (Nasdaq: RPRX) hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Das Unternehmen wird am 5. September 2024 um 9:15 Uhr ET in einem Kamingespräch vorgestellt. Diese Veranstaltung bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Geschäftstätigkeit und die Strategie von Royalty Pharma zu gewinnen.
Die Präsentation wird über Webcast auf der offiziellen Website des Unternehmens, insbesondere auf der 'Veranstaltungen'-Seite im Bereich 'Investoren', zugänglich sein. Für diejenigen, die live nicht teilnehmen können, wird der Webcast mindestens dreißig Tage lang archiviert, sodass auch später eine Betrachtung möglich ist. Diese Teilnahme unterstreicht das Engagement von Royalty Pharma, mit der Investorencommunity zu interagieren und ihre Sichtweise auf den Gesundheitssektor zu teilen.
- None.
- None.
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley’s 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When is Royalty Pharma (RPRX) presenting at Morgan Stanley's Healthcare Conference?
How can I watch Royalty Pharma's (RPRX) presentation at the Morgan Stanley conference?
Will Royalty Pharma's (RPRX) Morgan Stanley conference presentation be available after the event?
What type of presentation will Royalty Pharma (RPRX) give at the Morgan Stanley Healthcare Conference?
